Time on boards
- Boards served
- 3
- Current seats
- 3
- Board service
- 8 years
- Director since
- 2023
8 years of board service in total across 3 boards, counting each seat separately. Longest: Candel Therapeutics Inc., 3 years.
Chief executive roles
Weak · grade F
Out of 100, from shareholder return, dividends, growth and acquisitions.
Partial: only 20% of the scoring weight is on file.
- Revenue growth 20%
- 0
-15.9% a year in revenue
20% of the scoring weight is on file. Figures cover December 2023 – December 2025.
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Milestone Pharmaceuticals Inc. June 10, 202685.7%
-
Emergent BioSolutions Inc. April 29, 202694.2%
-
Milestone Pharmaceuticals Inc. June 10, 202575.6%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Apr 29, 2026 | Emergent BioSolutions Inc. | Grant or award | +187,708 | — | — |
| Mar 5, 2026 | Emergent BioSolutions Inc. | Shares withheld for tax | −37,055 | $8.44 | $312,744 |
| Jul 11, 2025 | Milestone Pharmaceuticals Inc. | Grant or award | +100,000 | — | — |
| Jun 25, 2025 | Candel Therapeutics Inc. | Grant or award | +64,239 | $4.67 | $299,996 |
| May 13, 2025 | Emergent BioSolutions Inc. | Open-market purchase | +60,000 | $5.83 | $349,800 |
| Mar 6, 2025 | Emergent BioSolutions Inc. | Grant or award | +282,500 | — | — |
Questions about Joseph C. Papa
What boards is Joseph C. Papa on?
Joseph C. Papa sits on the boards of Candel Therapeutics Inc., Emergent BioSolutions Inc. and Milestone Pharmaceuticals Inc.
What company is Joseph C. Papa the CEO of?
Joseph C. Papa has been President and CEO of Emergent BioSolutions Inc. since February 2024.
How long has Joseph C. Papa served on boards?
Our records show at least 8 years of board service across 3 boards, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.